Adjunct intra-arterial alteplase after thrombectomy improved 90-day functional recovery in LVO stroke (57.5% vs 42.5%). Headache occurs in 46% of hemorrhagic stroke patients; only 21.8% of stroke/TBI patients receive inpatient rehab.
Grifols has launched FESILTY (fibrinogen, human-chmt) in the U.S., a fibrinogen concentrate FDA-approved in December 2025 for acute bleeding episodes in patients with congenital fibrinogen deficiency. The highly purified product, developed by Biotest, enables rapid fibrinogen restoration and can be reconstituted in approximately three minutes.
The FDA approved Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic therapies. In TRANSCEND FL, the CAR T therapy showed a 95.5% overall response rate and 62.1% complete response rate.
The European Commission expanded Hympavzi approval to patients 12 and older with hemophilia A or B with inhibitors. Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy.
Nereus (tradipitant) is now commercially available for prevention of motion-induced vomiting. Vanda has launched a phase 3 trial in GLP-1 users, building on phase 2 results showing a 50% relative reduction in vomiting.
Norovirus has been making its rounds again during the winter season, causing vomiting, diarrhea and stomach cramps that usually clear within one to three days. There is no specific medication, and hydration, bland foods and strict handwashing are the main measures recommended.
The FDA has announced plans to crack down on active pharmaceutical ingredients used in compounded GLP-1 drugs and warned about the risks of these products. The agency has cited counterfeit products, non-FDA-approved ingredients and more than 1,000 adverse event reports tied to compounded semaglutide and tirzepatide.
Two phase 3 trials found upadacitinib 15 mg significantly improved facial and total repigmentation versus placebo at 48 weeks in nonsegmental vitiligo. The 614-patient studies also showed continued improvement over time and a safety profile consistent with prior use.
The FDA has expanded approval of GSK's Arexvy RSV vaccine to include adults aged 18 to 49 years at increased risk for lower respiratory tract disease, based on phase 3b trial data showing noninferior immune response.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after at least one prior therapy, and accepted a new drug application for iberdomide plus daratumumab and dexamethasone with a PDUFA date of August 17, 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07764783 |
Visual Instillation of Sphenopalatine-block Intervention for ONgoing Migraine |
NOT_YET_RECRUITING | PHASE2 |
| NCT07754266 |
Headache Ear Auditory Dizziness Sinus (HEADS) Registry |
RECRUITING | |
| NCT07725198 |
Immediate Neuromuscular Responses of the Obliquus Capitis Inferior Following Upper Cervical Manual Therapy |
RECRUITING | NA |
| NCT07699549 |
Long-term Atogepant in Real-world Practice |
COMPLETED | |
| NCT07661758 |
Intravenous Lidocaine to Prevent Post-Fundal Pressure Headache During Cesarean Section |
RECRUITING | PHASE3 |
| NCT07629141 |
Muscle Position and Dry Needling Efficacy |
RECRUITING | NA |
| NCT07587398 |
The Effectiveness of Acupuncture on Headaches in Women Undergoing IVF Egg Stimulation |
COMPLETED | NA |
| NCT07553533 |
Utilization of 60-Day Peripheral Nerve Stimulation of the Occipital Nerves for the Treatment of Headache |
ENROLLING_BY_INVITATION | |
| NCT07494383 |
Sphenopalatine Ganglion Block for Post-Dural Puncture Headache |
COMPLETED | NA |
| NCT07487649 |
Treatment Response in Patients With Medication-Overuse Headache |
RECRUITING |
